亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

奧地利Polymun
Polymun是一家CRO企業(yè)，盈利用于投資新的產(chǎn)品線和技術(shù)平臺(tái)。核心技術(shù)是哺乳動(dòng)物和微生物細(xì)胞表達(dá)技術(shù)。中和型HIV-1 抗體最有特色，四個(gè)克隆C2F5， C2G12 ，C4E10，b12已在世界范圍內(nèi)作為金標(biāo)準(zhǔn)。另有HIV-1 抗原和蛋白，重組人和豬的胰酶，過氧化物歧化酶等。

Polymun was founded in 1992 by Prof. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. The last inspection has taken place in September 2008.

Competence & Services
The core competence of Polymun is the development and manufacture of biopharmaceuticals, using both mammalian mammalian and microbial cell technology. A fine example are Polymun′s broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.

Staff
Polymun employs a team of more than 40 dynamic and highly qualified scientists, technicians and support staff. The average age is 34, and 45% hold an academic title, mostly in natural sciences such as biotechnology, biology or chemistry. About 50% graduated from technical schools or colleges. Men and women are found equally in all positions. Polymun is also giving several of its employees the opportunity to perform their master or doctor theses within the scope of the company. With quality and reliability as a pre-requisite basis, innovation and creativity are strongly encouraged at Polymun.

Network
Located within the campus of the University of Natural Resources and Applied Life Sciences, Polymun has close contacts to the Institute of Applied Microbiology (IAM). The fruitful scientific dialog and the broad methodological competence are of mutual benefit.
Polymun is partner in one project of the EU 6th Framework Program (A HREF="http://www.altaweb.eu/europrise" target="_blank" title="EUROPRISE - Website" >EUROPRISE) and in two projects of the EU 7th Framework Program (EuroNeut-41, CHAARM). Furthermore, Polymun is active in two projects of the Grand Challenges in Global Health sponsored by the Bill & Melinda Gates Foundation and the Wellcome Trust. Polymun is part of the competence center of BioMolecular Therapeutics (BMT).

Partners
Polymun′s customers and partners include renowned companies such as GlaxoSmithKline, Sanofi Pasteur, Baxter AG, Merck Serono, Apeiron Biologics AG and Vogelbusch GmbH as well as non-profit organizations such as St. George's University of London, the Children's Cancer Research Institute (CCRI) and the International AIDS Vaccine Initiative (IAVI).